Demand for Ozempic and Wegovy is reaching new heights. Here’s why it can go even higher. | The motley fool
Ozempic and Wegovy. These are the two drugs that are the focus of any income or press release coming fromNovo Nordisk(NVO -0.09%). The Danish company struck gold not only with a cutting-edge diabetes drug in Ozempic, but also with an impressive weight loss treatment in Wegovy. Both drugs actually help… Continue Reading Demand for Ozempic and Wegovy is reaching new heights. Here’s why it can go even higher. | The motley fool